Navigating the Crisis of Multidrug-Resistant Infections in Infants: Regional Variability and Global Solutions

1. Introduction

Superbacteria represent one of the most concerning threats to global public health (1, 2). According to the World Health Organization (WHO), antibiotic-resistant infections cause approximately 1.27 million direct deaths annually worldwide and contribute to nearly 5 million additional deaths (3). The most affected regions include South Asia and sub-Saharan Africa, where bacterial resistance rates reach critical levels (47). The most concerning superbacteria are Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii, and Pseudomonas aeruginosa, all of which show increasing resistance to multiple drugs (8, 9). In India, it is estimated that over 200,000 deaths per year are related to resistant infections, whereas in China and Pakistan, the figures exceed 100,000 and 50,000, respectively. Resistance has been particularly observed in key antibiotics, such as colistin, carbapenems, and third-generation cephalosporins, limiting treatment options $\left(\mathrm{10,11}\right)$. These microorganisms exhibit extreme resistance to multiple antibiotics, which makes treatment with conventional drugs difficult or impossible. Their proliferation has been driven by the indiscriminate use of antibiotics in medicine and livestock as well as deficiencies in infection control within healthcare systems (12, 13).

Globally, some countries present a higher risk due to various factors such as high population density, limited access to adequate treatments, and the presence of healthcare systems with poor infrastructure (14, 15). Among the countries with the highest incidence of superbacterial infections are India, China, and Pakistan, where unrestricted access to antibiotics has fostered the emergence of antibiotic-resistant bacteria. In India, approximately $70\mathrm{\%}$ of bacterial infections are resistant to at least one last-line antibiotic. China faces a growing number of carbapenem-resistant Acinetobacter baumannii infections, while Pakistan struggles with the spread of multidrug-resistant strains of Escherichia coli. In India, approximately 57% of Klebsiella pneumoniae cases show resistance to carbapenems, while in China, $45\mathrm{\%}$ of Acinetobacter baumannii infections are resistant to multiple drugs. In Pakistan, $40\mathrm{\%}$ of Escherichia coli strains have developed resistance to third-generation cephalosporins (16-20). Likewise, nations in Latin America, such as Brazil and Mexico, face significant challenges owing to the lack of effective measures to control the spread of these microorganisms. In Latin America, Brazil and Mexico have reported a significant increase in resistant infections due to uncontrolled antibiotic use and the lack of strict regulations in their sale (21-24). In Africa, countries such as Nigeria and South Africa have reported alarming cases of resistance to colistin and carbapenems, with bacterial resistance rates exceeding $50\mathrm{\%}$ in hospital infections exacerbated by the scarcity of healthcare infrastructure and infection control programs, leaving patients without effective treatment options (6, 25, 26). Additionally, poor hospital infrastructure in these regions contributes to the rapid spread of nosocomial infections, making it difficult to contain superbacteria in clinical settings. The lack of access to adequate diagnostics and effective treatments remains a key challenge in these areas, exacerbating the antimicrobial resistance crisis (Figure 1).

Studies on superbacteria are essential for the development of new prevention and treatment strategies. Superbacteria are microorganisms that have acquired resistance to multiple antibiotics through genetic mutations or the transfer of resistance genes between bacteria. Scientific research in this field has enabled the identification of new antibiotics and therapeutic alternatives, such as phage therapy (viruses that attack bacteria), antimicrobial peptides, and gene-editing therapies such as CRISPR-Cas9. Additionally, the implementation of rational antimicrobial use policies is fundamental for curbing the spread of resistance. It is also crucial to develop and apply rapid diagnostic tests that allow for precise identification of resistant infections and reduce unnecessary antibiotic use. The implementation of rational antimicrobial use policies, including appropriate antibiotic prescriptions, regulation of their sale, and monitoring of bacterial resistance, is key to the spread of these infections. In this context, the pediatric population, particularly neonates (newborns in their first 28 days of life), infants (up to the first year), and children (up to 12 years), represents a highly vulnerable group. The development of immune systems, immature gut microbiota, and increased exposure to hospital environments makes antibiotic-resistant infections especially dangerous. They face an elevated risk due to their immunological fragility and the need for invasive procedures, such as mechanical ventilation and intravenous catheters, which can facilitate the entry of resistant bacteria into their bodies. In neonatal intensive care units (NICUs), according to the WHO, resistant infections are responsible for approximately 214,000 neonatal deaths per year, with Klebsiella pneumoniae and Acinetobacter baumannii being the most common bacteria in these infections. Morbidity and mortality in this population increase significantly in resource-limited countries where access to last-line treatments is scarce. According to previous studies, in some regions, the mortality rate from resistant infections in neonates can exceed $40\mathrm{\%}$, highlighting the urgent need to strengthen prevention and treatment measures aimed at this population (Figure 2).

Considering this issue, it is crucial to strengthen epidemiological surveillance, promote awareness of the prudent use of antibiotics, and foster research into innovative treatments. Epidemiological surveillance should include the implementation of systems, such as the WHO’s Global Antimicrobial Resistance Surveillance System (GLASS), which allows for the monitoring and analysis of resistance trends globally. Additionally, it is essential to carry out public awareness campaigns, such as the World Antimicrobial Awareness Week (WAAW), which educates people about the proper use of these medications. Research into innovative treatments includes the development of new antibiotics, exploration of alternative therapies, such as bacteriophage use, and the design of vaccines to prevent bacterial infections. International cooperation and commitment of healthcare systems will be decisive in curbing the spread of these bacterial threats. Programs such as WHO’s Global Action Plan (GAP) on Antimicrobial Resistance and initiatives by the Global Antibiotic Research and Development Partnership (GARDP) are the key examples of collaborative efforts. Through a coordinated and multidisciplinary approach, it will be possible to protect future generations from the devastating effects of superbacteria.

2. Objective

The main objective of this research study is to conduct a revision and meta-analysis based on the available literature, to enlighten society about this problem and analyze the actual solutions that have been given, whether superbacteria are most common, especially in infants and baby populations. For this purpose, a systematic review and meta-analysis of research published between 1990 and 2024 was conducted to ensure focused and systematic assessment. The research question will be defined using the PICO framework: diseases produced by superbacteria in infants and neonatal populations worldwide.

3. Methodology

Literature Search

The initial step was to conduct a systematic review involving drafting a detailed protocol that outlined the objectives, eligibility criteria, and methodological approach. It has been conducted according to the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidelines, which provide a standardized framework for protocol development (27-29). Accordingly, a systematic search was performed using the following databases: Cochrane Library (30), EMBASE (31), MEDLINE (32), and CINAHL (33). Scientific reports included in the study were obtained using the following MeSH search terms: “(superbacteria) AND (infants) AND (neonatal).”

Study Eligibility Criteria

The research question will be defined using the PICO framework, which involves population, intervention, comparator, and outcomes of interest. The following inclusion criteria were used for screening: (1) infants aged 0-6 years old; (2) superbacterial infections; (3) all countries included; and (4) articles published between 1990 and2024. The exclusion criteria were (1) patients over 7 years of age, (2) no bacterial infections, and (3) non-controlled trials.

Study Selection

Both the titles and abstracts of articles that met the criteria were independently screened by two authors of the present study using Rayyan software (Rayyan systematic review software, India). Subsequently, all authors acted as peer reviewers by independently assessing the full-text articles of potentially eligible studies. In the case of a lack of consensus between the two reviewers involved in the screening or assessment of the full texts, the authors discussed the conflict and reached an agreement. We documented the reasons for the exclusion of the full-text articles that we assessed.

Quality Assessment and Risk of Bias

Studies included in the meta-analysis were carried out using previously defined superbacterial cell lines. In this type of study, it was not possible to analyze bias following the methodology proposed in the Cochrane manual (30), as it is specific to the evaluation of clinical studies.

Data Extraction

Data extraction from the selected studies was performed using the standardized procedure developed by PRISMA (28, 29, 34), including the following information: (1) complete author name, (2) year of publication, (3) superbacterial name, (4) population age, and (5) effect on the patient. Rayyan software was chosen to perform the sifting because it facilitates collaboration with Cochrane to improve the production and use of systematic reviews for healthcare and well-being.

Statistical Analysis

Where feasible, a quantitative synthesis in the form of a meta-analysis will be conducted using software such as Review Manager (RevMan), R (meta package), or STATA. Effect measures will be chosen based on the outcome type: risk ratios (RR) or odds ratios (OR) with $95\mathrm{\%}$ confidence intervals (CIs) for dichotomous outcomes and mean difference (MD) or standardized mean difference (SMD) for continuous outcomes. Model selection will depend on the degree of heterogeneity, with a fixed-effects model used for low heterogeneity and a random-effects model employed when heterogeneity was substantial. Heterogeneity will be assessed using the ${\mathrm{I}}^2$ statistic and chi-squared test, with ${\mathrm{I}}^2$ values of $0-25\mathrm{\%}$ considered low, $25-50\mathrm{\%}$ moderate, and over $50\mathrm{\%}$ high. Subgroup analyses may be conducted based on study characteristics such as population or geographical region, and sensitivity analyses will be performed to evaluate the robustness of the findings.

Ethical Considerations

Because the review will be based entirely on previously published data, formal ethical approval is generally not required. Nonetheless, the review will adhere to ethical standards in research and reporting, including respect for data privacy and compliance with the accepted guidelines for the ethical publication of scientific work.

4. Results

The three outcomes pursued in the present study were: (1) determine whether the effect of each superbacterium on the diseases and their common resistance patterns; (2) analyze the effect of superbacteria around different countries; and (3) determine whether cell cycle arrest is the molecular target of grape polyphenols on leukemia cells.

A flowchart describing the process of selecting publications to be included in the study is presented in Table 1, which summarizes the included articles and the information extracted to evaluate the three outcomes stated above. Once duplicate results were removed, 5131 articles were selected as a result of the search carried out. The Titles and Abstracts of these articles were reviewed by the authors against the previously established eligibility criteria. Accordingly, 5016 articles were excluded from the study because they did not fulfill the criteria. The full text of the remaining 115 articles was screened.

Overall, 75 studies met the criteria, but only 37 articles, which included quantitative data useful for statistical analysis, were selected for the meta-analysis (Table 2) (36-72).

As illustrated in Table 3, the following data are presented: first, the frequency of the different bacterial species identified in a specific study or analysis and second, the percentage of each species. The most prevalent species identified was Escherichia coli, with a frequency of nine cases, representing $14.7\mathrm{\%}$ of the total. Klebsiella pneumoniae was the second most prevalent species, with nine cases representing $13.2\mathrm{\%}$ of the total species. Pseudomonas aeruginosa was mentioned eight times, representing $11.8\mathrm{\%}$ of the findings. Acinetobacter baumannii was documented on seven occasions, corresponding to $10.3\mathrm{\%}$ of the total population. Enterobacter cloacae and Staphylococcus aureus were identified in $6.8\mathrm{\%}$ of the samples. Group B Streptococcus was documented at a frequency corresponding to $7.3\mathrm{\%}$ of the samples. Furthermore, the prevalence of vancomycin-resistant Enterococcus was documented in four cases, accounting for $5.9\mathrm{\%}$ of the total observed cases. The fungal species Candida auris and the bacterium Clostridium difficile were identified in $4.4\mathrm{\%}$ of the cases, with a frequency of three occurrences each.

Table 4 presents the frequencies and percentages of various patient groups. The data indicated that the largest group of patients required intensive care, with 121 patients representing 17. This is equal to $6\mathrm{\%}$ of the total. The second largest group was that of NICU patients, with 101 cases, representing $14.7\mathrm{\%}$ of the total. The total number of pediatric patients with urinary tract infections (UTIs) was 81, representing $11\mathrm{\%}$ of the total. Community-acquired infections were observed in 71 patients, constituting $10.3\mathrm{\%}$ of all the cases. Six patients, which is $8.8\mathrm{\%}$ of the total, had neonatal sepsis. The study revealed that both liver transplant patients and those afflicted with ventilator-associated pneumonia constituted five patients each, thereby accounting for $7.3\mathrm{\%}$ of the total sample. Finally, the patient groups infected with the novel coronavirus ($n=4$) and those suffering from pediatric oncology ($n=4$) accounted for $5.9\mathrm{\%}$ of the total. The following table provides a concise summary of the distribution of various patient groups in a clinical setting.

The data presented in Table 5 demonstrate the distribution of specific parameters in various countries along with their respective percentages. India is at the top of the list, with a score of 8, corresponding to $14.8\mathrm{\%}$ of the total. Spain had a score of 7, representing 13.0% of the total. Portugal and Tunisia were assigned the same score of 6, representing $11.1\mathrm{\%}$ each. China is the second-highest-ranked country, with a score of 5, which equates to $9.3\mathrm{\%}$. Yemen and Pakistan had scores of 4 and 3, representing $7.4\mathrm{\%}$ and $5.6\mathrm{\%}$, respectively. Romania also had a score of 3, equivalent to $5.6\mathrm{\%}$. The table concludes with an overall figure of 10, which constitutes $18.5\mathrm{\%}$ of the total. This table provides a comparative overview of the selected countries in relation to a specific parameter, thus enabling an assessment of their performance or representation in this context.

Table 6 presents the prevalence of various antibiotic resistances among the sample population. The data indicates that beta-lactam resistance is the most prevalent, occurring in twelve cases, representing $20.7\mathrm{\%}$ of the total. Carbapenem resistance was identified in ten cases, constituting $17.2\mathrm{\%}$ of the total. Furthermore, the presence of Extended-Spectrum Beta-Lactamase (ESBL)-producing organisms was observed in nine cases, constituting $15\mathrm{\%}$ of the total. $5\mathrm{\%}$ Fluoroquinolone resistance has been documented in eight cases, constituting $13.8\mathrm{\%}$ of the total. As illustrated in the following table, other forms of resistance include vancomycin resistance in six cases ($10.3\mathrm{\%}$) and macrolide resistance in five cases (8.6%). This table highlights the varying degrees of antibiotic resistance in the study group.

Taking all the data together, a more comparative and complete Table 7 can be built to collect all these comparisons and observe the relationships between the superbacteria, their resistance, and the population affected in the different countries.

Escherichia coli (14.7%) and Klebsiella pneumoniae (13.2%) were the most frequently reported drug-resistant bacteria. Pseudomonas aeruginosa ($11.8\mathrm{\%}$) and Acinetobacter baumannii ($10.3\mathrm{\%}$) were also of significant concern. Regarding the most affected populations, several resistant bacteria are prevalent in neonates and children, increasing hospitalization risks, such as ICU patients ($17.6\mathrm{\%}$) and NICU patients ($14.7\mathrm{\%}$) are at the highest risk, and pediatric UTI cases ($11.8\mathrm{\%}$) and community-acquired infections ($10.3\mathrm{\%}$) are also major concerns. The potential use of Ceftolozane/Tazobactam in pediatric cases with severe multidrug-resistant infections is emerging. The most affected countries have widespread antibiotic resistance issues, and the resistance patterns differ across regions, emphasizing the need for localized surveillance. Focusing on the most concerning resistance types, most bacteria studied exhibit resistance to multiple antibiotic classes, making treatment difficult, such as beta-lactam resistance ($20.7\mathrm{\%}$), which is the most frequent, or carbapenem resistance, and ESBL production highlights severe antimicrobial threats. Other pathologies such as ventilator-associated pneumonia are commonly linked to Pseudomonas aeruginosa and Acinetobacter baumannii infections. Antibiotic resistance and the gut microbiome produced by early antibiotic exposure can increase the resistant bacterial populations in the gut. A significant presence of multidrug-resistant bacteria has also been detected in Liver Transplant Patients, with a high intestinal dominance by MDR organisms correlated with extraintestinal spread and infection. Pregnancy-related UTI risk: Pregnant women with MDR gram-negative UTIs have an increased risk of pyelonephritis. Candidemia in COVID-19 patients: Higher prevalence of multidrug-resistant Candida auris infections, especially in ICU settings.

5. Discussion

The emergence of multidrug-resistant (MDR) bacterial strains represents a significant public health concern, affecting diverse geographical areas and patient demographics, particularly those within healthcare facilities (73). The available data on antimicrobial resistance (AMR) indicate trends, particularly among hospitalized patients with compromised immune systems. Key pathogens, including Escherichia coli and Klebsiella pneumoniae, often cause urinary tract infections, bloodstream infections, and neonatal sepsis. The proliferation of extended-spectrum beta-lactamase (ESBL)-producing strains has led to a paucity of treatment options, rendering carbapenems the preferred choice for cases of severe infection. However, the emergence of carbapenem-resistant Enterobacteriaceae (CRE) has led to the need for alternative treatments such as colistin and tigecycline. Neonates and children exhibit heightened vulnerability owing to their underdeveloped immune systems and frequent exposure to hospital environments. This exposure, among other factors, contributes to elevated mortality rates from resistant infections in neonatal intensive care units (NICUs) (73-75).

Infections caused by vancomycin-resistant Staphylococcus aureus (VRSA) and methicillin-resistant Staphylococcus aureus (MRSA) pose a particularly high risk to immunocompromised pediatric patients and liver transplant recipients (76-78). Ventilator-associated pneumonia (VAP) has been observed to demonstrate resistance issues analogous to those of bacteria, such as Pseudomonas aeruginosa. The horizontal transfer of resistance genes, such as the vanA operon from resistant Enterococcus, exacerbates this problem (79-81). The dissemination of MDR bacteria from healthcare facilities to communities is a matter of significant concern, particularly in light of inadequate regulatory oversight regarding antibiotic utilization. The emergence of resistant strains such as Neisseria gonorrhoeae and Shigella underscores the need for comprehensive public health strategies (73, 82-85).

Exposure to antibiotics during early life has been shown to play a significant role in the development of antibiotic-resistant bacteria within the gut microbiota. This phenomenon not only increases the likelihood of future infections, but also promotes the transfer of resistance genes within communities. The increasing global burden of AMR is exacerbated by inappropriate antibiotic use, especially in resource-limited areas. Escherichia coli has demonstrated notable resistance to various antibiotics, with a high prevalence of ESBL-producing strains observed in multiple countries. Methicillin-resistant Staphylococcus aureus (MRSA) remains a major concern, particularly in resource-constrained environments (86-92). Recent advancements in antibiotic therapies, including ceftaroline and tedizolid, hold promise for combating resistant infections. However, the emergence of resistant strains highlights the need for continuous surveillance and vigilance. Innovative treatment options such as bacteriophage therapy and antimicrobial peptides are currently under investigation. A multifaceted strategy is imperative to address this challenge, encompassing international collaboration, enhanced local surveillance, and public education to promote judicious antibiotic usage. Key organizations, such as the World Health Organization (WHO), have initiated systems, such as the Global Antimicrobial Resistance Surveillance System (GLASS), to track resistance patterns and support global efforts against MDR bacteria (93-95). Strategies also include hospital-based Antimicrobial Stewardship Programs (ASPs) to ensure proper antibiotic use, reduce unnecessary prescriptions, and control the use of vital antibiotics such as carbapenems. Infection control practices, such as strict hand hygiene and sanitation in hospital environments, are of utmost importance (96-99). Moreover, the implementation of vaccination programmes targeting bacterial infections has led to a concomitant reduction in the utilization of antibiotics. The utilization of surveillance systems such as GLASS is imperative for the tracking and comprehension of resistance patterns.

This study underscores the need for expeditious diagnostic tests to identify resistant infections and curtail unwarranted broad-spectrum antibiotic prescriptions from animals. Furthermore, it underscores the necessity of national action plans to combat AMR and the imperative for enhanced infection control measures, precise antibiotic treatment, and comprehensive programs to address the escalating threat of MDR infections (100-104).

6. Conclusions

This research helps us to understand the complexity of the superbacteria resistance problem that we already suffer in some countries, especially in infants and the neonatal population, which has led us to identify a few of the most harmful superbacteria. Therefore, it is imperative to explore combination therapies and develop novel drugs to enhance the effectiveness of antibiotics. The increasing prevalence of multidrug-resistant (MDR) bacteria represents a significant global health threat, complicating the treatment of a range of infections caused by well-known pathogens such as Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus. These superbacteria have emerged in hospitals and communities, posing a significant challenge to the public health systems worldwide. The acceleration of this issue can be attributed to two factors: inadequate antibiotic stewardship and excessive use of antibiotics. The latter is particularly problematic in regions with limited resources. The dissemination of pathogens has expanded beyond healthcare facilities to community settings, thereby posing a threat to both healthy individuals and those with compromised immune systems. This situation emphasizes the need for comprehensive public health strategies, including enhanced infection control measures, educational campaigns to promote optimal antibiotic stewardship, and improved surveillance systems. To address these challenges, alternative treatments are currently being explored, including bacteriophage therapy in new diagnostic and therapeutic strategies, which happen to be essential. The use of rapid diagnostic tools has the potential to expedite the identification of resistant pathogens, thereby mitigating the need for the indiscriminate use of broad-spectrum antibiotics. There is a pressing need for sustained investment in research and international collaboration, fostering a dynamic and cooperative environment to effectively combat the ever-evolving resistance. The emergence of superbacteria can be mitigated through the implementation of prevention strategies, development of innovative treatments, and promotion of international collaboration, thereby ensuring public health on a global scale.